TGF-β-Induced TMEPAI Attenuates the Response of Triple-Negative Breast Cancer Cells to Doxorubicin and Paclitaxel

References

• Wu G, Chen Y-G, Ozdamar B, et al. Structural basis of Smad2 recognition by the Smad anchor for receptor activation. Science. 2000;287(5450):92–97. doi:10.1126/science.287.5450.92
   PubMed Web of Science ®Google Scholar
• Xu LL, Shanmugam N, Segawa T, et al. A novel androgen-regulated gene, PMEPA1, located on chromosome 20q13 exhibits high level expression in prostate. Genomics. 2000;66(3):257–263. doi:10.1006/geno.2000.6214
   Web of Science ®Google Scholar
• Xu LL, Shi Y, Petrovics G, et al. PMEPA1, an androgen-regulated NEDD4-binding protein, exhibits cell growth inhibitory function and decreased expression during prostate cancer progression. Cancer Res. 2003;63(15):4299–4304.
   Web of Science ®Google Scholar
• Vo Nguyen TT, Watanabe Y, Shiba A, Noguchi M, Itoh S, Kato M. TMEPAI/PMEPA1 enhances tumorigenic activities in lung cancer cells. Cancer Sci. 2014;105(3):334–341. doi:10.1111/cas.12355
   Web of Science ®Google Scholar
• Tanner MM, Tirkkonen M, Kallioniemi A, et al. Increased copy number at 20q13 in breast cancer: defining the critical region and exclusion of candidate genes. Cancer Res. 1994;54(16):4257–4260.
   Web of Science ®Google Scholar
• Singha PK, Pandeswara S, Geng H, Lan R, Venkatachalam MA, Saikumar P. TGF-β induced TMEPAI/PMEPA1 inhibits canonical Smad signaling through R-Smad sequestration and promotes non-canonical PI3K/Akt signaling by reducing PTEN in triple negative breast cancer. Genes Cancer. 2014;5(9–10):320.
   Google Scholar
• Brunschwig EB, Wilson K, Mack D, et al. PMEPA1, a transforming growth factor-β-induced marker of terminal colonocyte differentiation whose expression is maintained in primary and metastatic colon cancer. Cancer Res. 2003;63(7):1568–1575.
   Web of Science ®Google Scholar
• Ishkanian AS, Mallof CA, Ho J, et al. High‐resolution array CGH identifies novel regions of genomic alteration in intermediate‐risk prostate cancer. Prostate. 2009;69(10):1091–1100. doi:10.1002/pros.20959
   Web of Science ®Google Scholar
• Rae FK, Hooper JD, Nicol DL, Clements JA. Characterization of a novel gene, STAG1/PMEPA1, upregulated in renal cell carcinoma and other solid tumors. Mol Carcinog. 2001;32(1):44–53. doi:10.1002/(ISSN)1098-2744
   Web of Science ®Google Scholar
• Azami S, Nguyen TTV, Watanabe Y, Kato M. Cooperative induction of transmembrane prostate androgen induced protein TMEPAI/PMEPA1 by transforming growth factor-β and epidermal growth factor signaling. Biochem Biophys Res Commun. 2015;456(2):580–585. doi:10.1016/j.bbrc.2014.11.107
   Web of Science ®Google Scholar
• Watanabe Y, Itoh S, Goto T, et al. TMEPAI, a transmembrane TGF-β-inducible protein, sequesters Smad proteins from active participation in TGF-β signaling. Mol Cell. 2010;37(1):123–134. doi:10.1016/j.molcel.2009.10.028
   Web of Science ®Google Scholar
• Bai X, Jing L, Li Y, et al. TMEPAI inhibits TGF-β signaling by promoting lysosome degradation of TGF-β receptor and contributes to lung cancer development. Cell Signal. 2014;26(9):2030–2039. doi:10.1016/j.cellsig.2014.06.001
   Web of Science ®Google Scholar
• Singha PK, Yeh I-T, Venkatachalam MA, Saikumar P. Transforming growth factor-β (TGF-β)–inducible gene TMEPAI converts TGF-β from a tumor suppressor to a tumor promoter in breast cancer. Cancer Res. 2010;70(15):6377–6383. doi:10.1158/0008-5472.CAN-10-1180
   Web of Science ®Google Scholar
• Sharma P. Biology and management of patients with triple-negative breast cancer. Oncologist. 2016;21(9):1050–1062. doi:10.1634/theoncologist.2016-0067
   PubMed Web of Science ®Google Scholar
• Anders CK, Abramson V, Tan T, Dent R. The evolution of triple-negative breast cancer: from biology to novel therapeutics. Am Soc Clin Oncol Educ Book. 2016;36:34–42. doi:10.14694/EDBK_159135
   Google Scholar
• Hudis CA, Gianni L. Triple-negative breast cancer: an unmet medical need. Oncologist. 2011;16(Supplement 1):1–11. doi:10.1634/theoncologist.2011-S1-01
   Web of Science ®Google Scholar
• Liu Y-X, Zhang K-J, Tang -L-L. Clinical significance of androgen receptor expression in triple negative breast cancer-an immunohistochemistry study. Oncol Lett. 2018;15(6):10008–10016. doi:10.3892/ol.2018.8548
   PubMed Web of Science ®Google Scholar
• Mina A, Yoder R, Sharma P. Targeting the androgen receptor in triple-negative breast cancer: current perspectives. OncoTargets Ther. 2017;10:4675. doi:10.2147/OTT
   PubMed Web of Science ®Google Scholar
• Giovannelli P, Di Donato M, Galasso G, Di Zazzo E, Bilancio A, Migliaccio A. The androgen receptor in breast cancer. Front Endocrinol. 2018;9.
   Web of Science ®Google Scholar
• Harvell DM, Spoelstra NS, Singh M, et al. Molecular signatures of neoadjuvant endocrine therapy for breast cancer: characteristics of response or intrinsic resistance. Breast Cancer Res Treat. 2008;112(3):475. doi:10.1007/s10549-008-9897-4
   Web of Science ®Google Scholar
• Luo S, Yang M, Lv D, et al. TMEPAI increases lysosome stability and promotes autophagy. Int J Biochem Cell Biol. 2016;76:98–106. doi:10.1016/j.biocel.2016.05.004
   PubMed Web of Science ®Google Scholar
• Zheng X, Carstens JL, Kim J, et al. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature. 2015;527(7579):525. doi:10.1038/nature16064
   PubMed Web of Science ®Google Scholar
• Fischer KR, Durrans A, Lee S, et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature. 2015;527(7579):472. doi:10.1038/nature15748
   PubMed Web of Science ®Google Scholar
• Mashiko D, Fujihara Y, Satouh Y, Miyata H, Isotani A, Ikawa M. Generation of mutant mice by pronuclear injection of circular plasmid expressing Cas9 and single guided RNA. Sci Rep. 2013;3:3355. doi:10.1038/srep03355
   PubMed Web of Science ®Google Scholar
• Wardhani BWK, Puteri MU, Watanabe Y, Louisa M, Setiabudy R, Kato M. TMEPAI genome editing in triple negative breast cancer cells. Med J Indones. 2017;26(1):14–18. doi:10.13181/mji.v26i1.1871
   Web of Science ®Google Scholar
• Lee A, Djamgoz MB. Triple negative breast cancer: emerging therapeutic modalities and novel combination therapies. Cancer Treat Rev. 2018;62:110–122. doi:10.1016/j.ctrv.2017.11.003
   PubMed Web of Science ®Google Scholar
• Hu Y, He K, Wang D, et al. TMEPAI regulates EMT in lung cancer cells by modulating the ROS and IRS-1 signaling pathways. Carcinogenesis. 2013;34(8):1764–1772. doi:10.1093/carcin/bgt132
   Web of Science ®Google Scholar
• Abdelaziz M, Watanabe Y, Kato M. PMEPA1/TMEPAI knockout impairs tumour growth and lung metastasis in MDA-MB-231 cells without changing monolayer culture cell growth. J Biochem. 2019;165(5):411–414. doi:10.1093/jb/mvz022
   Web of Science ®Google Scholar
• Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750–2767. doi:10.1172/JCI45014
   PubMed Web of Science ®Google Scholar
• Tseng L-M, Chiu J-H, Liu C-Y, et al. A comparison of the molecular subtypes of triple-negative breast cancer among non-Asian and Taiwanese women. Breast Cancer Res Treat. 2017;163(2):241–254. doi:10.1007/s10549-017-4195-7
   Web of Science ®Google Scholar
• Dai X, Cheng H, Bai Z, Li J. Breast cancer cell line classification and its relevance with breast tumor subtyping. J Cancer. 2017;8(16):3131. doi:10.7150/jca.18457
   PubMed Web of Science ®Google Scholar
• Rodríguez‑Rodríguez DR, Ramírez‑Solís R, Garza‑Elizondo MA, Garza‑Rodríguez MDL, Barrera‑Saldaña HA. Genome editing: a perspective on the application of CRISPR/Cas9 to study human diseases. Int J Mol Med. 2019;43(4):1559–1574. doi:10.3892/ijmm.2019.4112
   Web of Science ®Google Scholar
• Naito Y, Hino K, Bono H, Ui-Tei K. CRISPRdirect: software for designing CRISPR/Cas guide RNA with reduced off-target sites. Bioinformatics. 2014;31(7):1120–1123. doi:10.1093/bioinformatics/btu743
   Web of Science ®Google Scholar
• Amalia R, Abdelaziz M, Puteri MU, et al. TMEPAI/PMEPA1 inhibits Wnt signaling by regulating β-catenin stability and nuclear accumulation in triple negative breast cancer cells. Cell Signal. 2019;59:24–33. doi:10.1016/j.cellsig.2019.03.016
   PubMed Web of Science ®Google Scholar
• NCCN. National comprehensive cancer network guidelines: breast cancer version 1; March 14, 2019. Available from: www.nccn.org/professionals/physicians_gls/pdf.
   Google Scholar
• Mehanna J, Haddad FG, Eid R, Lambertini M, Kourie HR. Triple-negative breast cancer: current perspective on the evolving therapeutic landscape. Int J Women’s Health. 2019;11:431. doi:10.2147/IJWH.S178349
   PubMed Web of Science ®Google Scholar
• Barton VN, Gordon MA, Richer JK, Elias A. Anti-androgen therapy in triple-negative breast cancer. Ther Adv Med Oncol. 2016;8(4):305–308. doi:10.1177/1758834016646735
   Web of Science ®Google Scholar
• Wardhani BWK, Puteri MU, Watanabe Y, Louisa M, Setiabudy R, Kato M. Decreased sensitivity of several anticancer drugs in TMEPAI knockout triple-negative breast cancer cells. Med J Indonesia. 2019;28(2):110–115. doi:10.13181/mji.v28i2.2687
   Web of Science ®Google Scholar
• Xu Y, Chen S-Y, Ross KN, Balk SP. Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins. Cancer Res. 2006;66(15):7783–7792. doi:10.1158/0008-5472.CAN-05-4472
   Web of Science ®Google Scholar
• James M, Dixit A, Robinson B, Frampton C, Davey V. Outcomes for patients with non-metastatic triple-negative breast cancer in New Zealand. Clin Oncol. 2019;31(1):17–24. doi:10.1016/j.clon.2018.09.006
   Web of Science ®Google Scholar
• Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;740:364–378. doi:10.1016/j.ejphar.2014.07.025
   PubMed Web of Science ®Google Scholar
• Weaver BA. How Taxol/paclitaxel kills cancer cells. Mol Biol Cell. 2014;25(18):2677–2681. doi:10.1091/mbc.e14-04-0916
   PubMed Web of Science ®Google Scholar
• Lovitt CJ, Shelper TB, Avery VM. Doxorubicin resistance in breast cancer cells is mediated by extracellular matrix proteins. BMC Cancer. 2018;18(1):41. doi:10.1186/s12885-017-3953-6
   PubMed Web of Science ®Google Scholar
• Tacar O, Sriamornsak P, Dass CR. Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J Pharm Pharmacol. 2013;65(2):157–170. doi:10.1111/j.2042-7158.2012.01567.x
   PubMed Web of Science ®Google Scholar
• Singha PK, Pandeswara S, Geng H, et al. Increased Smad3 and reduced Smad2 levels mediate the functional switch of TGF-β from growth suppressor to growth and metastasis promoter through TMEPAI/PMEPA1 in triple negative breast cancer. Genes Cancer. 2019;10:5–6.
   Google Scholar
• Zheng K, He Z, Kitazato K, Wang Y. Selective autophagy regulates cell cycle in cancer therapy. Theranostics. 2019;9(1):104. doi:10.7150/thno.30308
   PubMed Web of Science ®Google Scholar
• Li L, Sun F, Chen X, Zhang M. ISL1 is upregulated in breast cancer and promotes cell proliferation, invasion, and angiogenesis. OncoTargets Ther. 2018;11:781. doi:10.2147/OTT
   Web of Science ®Google Scholar
• Zhang Y, Wang L, Gao P, et al. ISL1 promotes cancer progression and inhibits cisplatin sensitivity in triple-negative breast cancer cells. Int J Mol Med. 2018;42(5):2343–2352. doi:10.3892/ijmm.2018.3842
   Web of Science ®Google Scholar
• Huang R, Han J, Liang X, et al. Androgen receptor expression and bicalutamide antagonize androgen receptor inhibit β-catenin transcription complex in estrogen receptor-negative breast cancer. Cell Physiol Biochem. 2017;43(6):2212–2225. doi:10.1159/000484300
   PubMedGoogle Scholar